TY - CHAP
T1 - Introduction
AU - Prendergast, George C.
AU - Jaffee, Elizabeth M.
N1 - Funding Information:
Work in the authors' laboratories is supported by National Cancer Institute grants CA82222, CA100123, and CA109542 and the Lankenau Hospital Foundation (G.C.P.); by National Cancer Institute grants of the Specialized Program of Research Excellence in Gastrointestinal Cancer (CA62924) and Breast Cancer (CA88843); by the Avon Foundation for Breast Cancer Research and the National Cooperative Drug Discovery Group (U19CA72108); and by generous donations from the Goodwin Family and The Sol Goldman Pancreatic Research Center (E.M.J.). Dr. Jaffee is the Dana and Albert “Cubby” Broccoli Professor of Oncology. G.C.P. would like to acknowledge contributions from long-term collaborator A.J. Muller toward development of the perspectives offered in this chapter. G.C.P. declares competing financial interests as a significant stockholder and scientific advisory member at New Link Genetics Corporation, a biotechnology company that has licensed intellectual property to develop inhibitors of the immune suppressive enzyme IDO for combinatorial cancer treatment, as described in patents WO 2004 093871 “Novel methods for the treatment of cancer” (pending) and WO 2004 094409 “Novel IDO inhibitors and methods of use” (pending).
PY - 2007
Y1 - 2007
N2 - This chapter provides an introduction to the central concept of immunoediting. This fundamental process has three parts-immunosurveillance, immuneequilibrium, and immune escapewhich leads to control, stasis, or outgrowth of a malignancy. Immunoediting starts with the immune recognition and destruction of cells that have acquired the genetic and epigenetic alterations characteristic of the tumor cells, but at the same time, the selective pressure produced by immunoediting drives tumor evolution and progression. In this process, the cell intrinsic traits of cancer lead to the development of subclinical or occult lesions that are not clinically important until the cell-extrinsic traits have been achieved. The complex roles for inflammatory cells and altered immunity in the development of cell-extrinsic traits represent an increasingly important area for investigation. The chapter concludes by discussing several key aspects of immunosurveillance-the generation of innate and adaptive immune responses to the tumor cells, and the new classes of small molecule drugs termed as the molecular targeted therapeutics.
AB - This chapter provides an introduction to the central concept of immunoediting. This fundamental process has three parts-immunosurveillance, immuneequilibrium, and immune escapewhich leads to control, stasis, or outgrowth of a malignancy. Immunoediting starts with the immune recognition and destruction of cells that have acquired the genetic and epigenetic alterations characteristic of the tumor cells, but at the same time, the selective pressure produced by immunoediting drives tumor evolution and progression. In this process, the cell intrinsic traits of cancer lead to the development of subclinical or occult lesions that are not clinically important until the cell-extrinsic traits have been achieved. The complex roles for inflammatory cells and altered immunity in the development of cell-extrinsic traits represent an increasingly important area for investigation. The chapter concludes by discussing several key aspects of immunosurveillance-the generation of innate and adaptive immune responses to the tumor cells, and the new classes of small molecule drugs termed as the molecular targeted therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=84882520180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882520180&partnerID=8YFLogxK
U2 - 10.1016/B978-012372551-6/50065-1
DO - 10.1016/B978-012372551-6/50065-1
M3 - Chapter
AN - SCOPUS:84882520180
SN - 9780123725516
SP - 3
EP - 8
BT - Cancer Immunotherapy
PB - Elsevier Inc.
ER -